Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".
Leukemia & lymphoma（2023）
摘要
Click to increase image sizeClick to decrease image size Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.
更多查看译文
关键词
daratumumab,dexamethasone,real-world,lenalidomide-refractory
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要